Gilead Sciences, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
8.1
Buy
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
GILD
High-quality business with 41% return on equity and 29% profit margins.
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
BUY
Target $158.36 (+20.0%)
28 analysts
BUY
Target $129.74 (+17.2%)
27 analysts
Fundamentals
GILD
MRK
19.5×
Trailing P/E
15.2×
13.7×
Forward P/E
11.4×
28.9%
Profit Margin
28.1%
78.8%
Gross Margin
77.2%
40.7%
ROE
36.9%
4.7%
Revenue Growth
5.0%
23.4%
Earnings Growth
-19.3%
0.40
Beta
0.28
—
Price / Book
—
$163.8B
Market Cap
$273.5B
$95 – $157
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.